Vancomycin’s side effects depend heavily on how you receive it. Given intravenously (through a vein), the most common concerns are kidney damage, low blood pressure, and allergic-type reactions. Taken orally, the drug barely enters the bloodstream, so side effects are mostly limited to the gut: abdominal pain, nausea, and a distorted sense of taste.
Oral Vancomycin Side Effects
Oral vancomycin is prescribed almost exclusively for intestinal infections, particularly C. difficile. Because it’s poorly absorbed through the gut wall, it stays local, which limits the range of side effects significantly compared to the IV form.
The most frequently reported problems are abdominal pain, nausea, and dysgeusia, a distortion in the way food and drinks taste. Less common effects include fatigue, headache, diarrhea, gas, vomiting, back pain, swelling in the hands or feet, and fever. Although rare, there have been cases of kidney damage and hearing problems even with oral vancomycin, particularly in patients over 65 or those with pre-existing kidney issues.
Red Man Syndrome
The most distinctive reaction to IV vancomycin is red man syndrome, a flushing reaction that causes redness, itching, and warmth across the face, neck, and upper body. It is not a true allergy. Instead, it happens because vancomycin triggers certain immune cells to release histamine directly, without involving the allergic antibody pathway.
The reaction is closely tied to how fast the drug is infused. In one study, 80% of volunteers who received a standard dose over one hour developed symptoms, compared to only 30% of those who received the same dose over two hours. For this reason, hospital protocols typically require each dose to be infused over at least 60 minutes, with longer times for larger doses. Slowing the infusion rate or pre-treating with an antihistamine usually prevents or reduces the reaction.
Kidney Damage
Nephrotoxicity is one of the most serious concerns with IV vancomycin. The reported incidence ranges widely, from 5% to 43%, depending on risk factors. Those risk factors include higher drug levels in the blood, pre-existing kidney disease, obesity, dehydration, and the use of other kidney-damaging medications at the same time.
Older adults face elevated risk. The drug is cleared from the body primarily through the kidneys, and because kidney function naturally declines with age, vancomycin lingers longer in older patients. Studies comparing younger adults (average age 23) to older adults (average age 68) found the drug’s half-life was roughly 7 hours in younger patients but over 12 hours in older ones. That prolonged exposure increases the chance of kidney injury, which is why healthcare teams monitor kidney function closely throughout treatment and often use lower maintenance doses in elderly patients.
Current clinical guidelines from major infectious disease organizations recommend a monitoring approach called AUC-guided dosing, which tracks the drug’s total exposure in the body over 24 hours rather than relying on a single blood level measurement. This method has been shown to reduce kidney damage rates without compromising the drug’s effectiveness against infection.
Hearing Problems
Vancomycin can cause ototoxicity, meaning damage to the structures of the inner ear. This can show up as ringing in the ears (tinnitus), hearing loss, or problems with balance. In one study of patients on long-term vancomycin, about 8% experienced some worsening of hearing, ranging from mild to moderate-to-severe loss.
The good news is that vancomycin-related hearing damage is generally considered rare and, in most cases, reversible once the drug is stopped. Research suggests that reversibility depends on how high drug levels climb. Blood concentrations above 40 mcg/mL have been linked to reversible damage, while concentrations above 80 mcg/mL or the presence of pre-existing kidney problems are associated with irreversible hearing loss. If you notice ringing in your ears, muffled hearing, or dizziness during treatment, these are signs that should be reported promptly.
Blood Cell Changes
Vancomycin can affect the production and survival of blood cells, though this is uncommon. The best-documented hematologic side effect is a drop in a type of white blood cell called neutrophils, which occurs in up to 8% of patients. This typically doesn’t appear until at least 12 days into treatment, making it primarily a concern for people on longer courses.
A drop in platelets (the cells responsible for clotting) has also been reported, usually reaching its lowest point around 8 days after starting the drug, though it can happen later. Both of these blood cell changes appear to be immune-mediated, meaning the body’s own immune system mistakenly targets the cells, and both are generally reversible once vancomycin is discontinued.
IV Site Reactions
Phlebitis, or inflammation of the vein where the IV is placed, is a practical nuisance for many patients receiving vancomycin. Rates range from 0% to 18% depending on the concentration used and the infusion method. Continuous infusion carries a phlebitis rate of about 13%. Signs include pain, redness, or swelling at the IV site. Rotating IV sites and using appropriate dilution concentrations help reduce this risk.
DRESS Syndrome and Severe Skin Reactions
Rarely, vancomycin can trigger a severe drug reaction known as DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms). This is a potentially life-threatening condition that typically develops 2 to 9 weeks after starting the medication. It presents with a widespread, itchy rash that can spread to the palms and soles, high fever, swollen lymph nodes, and signs of organ damage, particularly to the liver and kidneys.
DRESS is frequently misdiagnosed initially because its symptoms overlap with other conditions, including infections and other severe drug reactions like Stevens-Johnson Syndrome. The hallmark combination to watch for is a new rash plus fever plus blood work showing elevated levels of a white blood cell type called eosinophils. Because the reaction develops weeks after starting treatment, it’s easy to overlook vancomycin as the cause, which can delay appropriate care.
Older Adults Face Higher Risks
If you’re over 65 or caring for someone who is, vancomycin’s side effect profile shifts meaningfully. Older adults clear the drug roughly 23% more slowly than younger patients, and they tend to accumulate higher tissue levels because the drug binds more extensively to tissues outside the bloodstream. In one comparison, the drug’s volume of distribution was 44% higher in elderly patients than in younger ones.
The practical result is that standard adult doses can produce dangerously high drug levels in older patients. Longer treatment duration compounds the problem, as extended courses are independently linked to higher rates of kidney toxicity. Blood level monitoring and kidney function testing are especially important in this age group to catch problems early.